Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Fig 8
Changes in GDMS at cycle 2 end and cycle 3 end by clinical response (any CC-486 treatment cycle).
NR = no response; R = response. Response categories include complete remission (CR), any hematologic improvement (HI), HI-erythroid, HI-platelet, HI-neutrophil, RBC transfusion.